Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plecanatide in IBS-C
NCT01722318Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Nov 2012
- Primary completion
- Apr 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of plecanatide in irritable bowel syndrome (IBS) (5 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Change From Baseline in Weekly Complete Spontaneous Bowel Movements Frequency at 12 weeks. Started Nov 2012; status: completed.
02
Drugs
plecanatide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT01722318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01722318.